Premium
Expression of a newly defined tumor‐rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I‐restricted cytotoxic T lymphocytes by SART3‐derived peptides
Author(s) -
Tsuda Naotake,
Murayama Kumiko,
Ishida Hyota,
Matsunaga Kazuko,
Komiya Setsuro,
Itoh Kyogo,
Yamada Akira
Publication year - 2001
Publication title -
journal of orthopaedic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1016/s0736-0266(00)90031-7
Subject(s) - cytotoxic t cell , human leukocyte antigen , immunology , antigen , class (philosophy) , medicine , biology , computer science , in vitro , genetics , artificial intelligence
Abstract We recently reported that a SART3 tumor‐rejection antigen possessing tumor epitopes is capable of inducing HLA class I‐restricted and tumor‐specific cytotoxic T lymphocytes in cancer patients. We studied the expression of the SART3 protein in musculoskeletal tumors to find a molecule for potential use in tumor‐specific immunotherapy. The SART3 was detected at protein levels in 100% of the osteosarcoma cell lines ( n = 20), in 50% of the musculoskeletal tumor tissue specimens ( n = 32), and at notable levels in 67% of osteosarcoma tissues ( n = 9) and malignant fibrous histiocytosis tissues ( n = 9), respectively. SART3‐derived peptides at positions 109‐118 and 315‐323 induced HLA‐A24‐restricted tumor‐specific cytoxic T lymphocytes from peripheral blood mononuclear cells of patients with osteosarcoma or malignant fibrous histiocytosis . These peptide‐induced cytotoxic T lymphocytes recognized HLA‐A24 + SART3 + osteosarcoma cells but not HLA‐A24 − or SART3 − cells. These results suggest that the SART3 protein and its derived peptides could be molecules appropriate for use in specific immunotherapies for approximately 60% of HLA‐A24 + patients with osteosarcoma or malignant fibrous histiocytosis. © 2001 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.